Sort   by:  
 Page size 
GenomicsIdentification of the primary target of the chemotherapeutic agent CX-5461 as a late step in transcription initiation by RNA Polymerase I
In recent years, several small molecule cytotoxic drugs have been identified as potential inhibitors of ribosome biogenesis (Drygin et al., 2011; Peltonen et al., 2014a; Peltonen et al., 2014b). CX-5461 is one such drug that has also demonstrated anticancer potential for a wide range of malignancies...
ORGANISM(S): Mus musculus 
2021-04-07 | E-MTAB-9242 | biostudies-arrayexpress
ProteomicsQuantitative analysis of the impact of CX-5461 on the proteome of Pancreatic ductal adenocarcinoma cells.
To reveal the effect of CX-5461 (a small-molecule inhibitor of ribosome biogenesis)on the proteome of Pancreatic Ductal Adenocarcinoma (PDAC) cells, we carried out two quantitative proteomics analyses, using tumour cells isolated from an inducible mouse model of PDAC (iKras PDAC) (Ying et al., 2012)...
ORGANISM(S): Mus musculus (Mouse) 
2023-02-12 | PXD038439 | Pride
Pdac  kras  cx-5461  tmt 
TranscriptomicsBCL-2 overexpression attenuates p53 stabilization and activation following RiBi inhibitors treatment
RNA-seq experiment performed in SUDHL-5 cells incubated with RiBi inhibitors (Doxorubicin, Actinomycin D, CX-5461) for 6h in the presence or absence of BCL-2.
ORGANISM(S): Homo sapiens 
2025-04-01 | E-MTAB-14977 | biostudies-arrayexpress
GenomicsExpression data from colorectal cancer cell lines and CX-5461 treatment
Expression data from colorectal cancer cell lines and CX-5461 treatment
PRJNA833432 | ENA
GenomicsRAD51 ChIP-seq post treatment with CX-5461
We discovered two small molecule drugs - CX-5461 and CX-3543 - with specific toxicity against BRCA deficiencies in cancer cells and xenograft models. Both CX-5461 and CX-3543 have been previously recognized as RNA pol I inhibitors. CX-5461 is in advanced phase 1 trials for treatment of lymphoma and ...
ORGANISM(S): Homo sapiens 
2016-12-06 | GSE90967 | GEO
TranscriptomicsExpression data from colorectal cancer cell lines and CX-5461 treatment
We demonstrate that CX-5461 treatment suppresses multiple canonical pathways and transcriptions factors We used microarrays to analyze the potential mechanism by which CX-5461 regulates gene expression.
ORGANISM(S): Homo sapiens 
2022-12-21 | GSE201899 | GEO
GenomicsCX-5461 and Doxorubicin activate a shared DNA damage–associated transcriptional response in human cardiomyocytes
CX-5461 and Doxorubicin activate a shared DNA damage–associated transcriptional response in human cardiomyocytes
PRJNA1289016 | ENA
GenomicsPhase 1 CX-5461 Trial (Canadian Cancer Trials Group Trial IND.231)
CX-5461 is a G-quadruplex stabilizer that exhibits synthetic lethality in homologous recombination (HR) deficient models. In this multicentre Phase Ib trial in patients with solid tumors, 40 patients were treated across 10 dose levels (50 - 650 mg/m2) to determine the recommended phase II dose (RP2D...
EGAS00001006173 | EGA
UnknownCX-5461 Preferentially Induces Top2α-Dependent DNA Breaks at Ribosomal DNA Loci.
Not available
S-EPMC11275095 | biostudies-literature
GenomicsComparative gene expression profiling of high-grade serous ovarian cancer cells exposed to cisplatin or CX-5461
Comparative gene expression profiling of high-grade serous ovarian cancer cells exposed to cisplatin or CX-5461
PRJNA1210505 | ENA
Sort   by:  
 Page size